Generic Zilxi Availability
Last updated on Dec 12, 2024.
Zilxi is a brand name of minocycline topical, approved by the FDA in the following formulation(s):
ZILXI (minocycline hydrochloride - aerosol, foam;topical)
-
Manufacturer: JOURNEY
Approval date: May 28, 2020
Strength(s): EQ 1.5% BASE [RLD]
Has a generic version of Zilxi been approved?
No. There is currently no therapeutically equivalent version of Zilxi available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zilxi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Topical tetracycline compositions
Patent 10,213,512
Issued: February 26, 2019
Inventor(s): Tamarkin Dov & Gazal Elana & Papiashvili Irakliy & Hazot Yohan & Schuz David & Keynan Rita
Assignee(s): FOAMIX PHARMACEUTICALS LTD.A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.
Patent expiration dates:
- October 1, 2030✓✓
- October 1, 2030
-
Compositions, gels and foams with rheology modulators and uses thereof
Patent 10,265,404
Issued: April 23, 2019
Inventor(s): Tamarkin Dov & Gazal Elana & Hazot Yohan & Schuz David & Papiashvili Irakliy
Assignee(s): Foamix Pharmaceuticals Ltd.The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.
Patent expiration dates:
- October 1, 2030✓
- October 1, 2030
-
Topical tetracycline compositions
Patent 10,322,186
Issued: June 18, 2019
Inventor(s): Tamarkin Dov & Gazal Elana & Papiashvili Irakliy & Hazot Yohan & Schuz David & Keynan Rita
Assignee(s): FOAMIX PHARMACEUTICALS LTD.A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity or the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.
Patent expiration dates:
- October 1, 2030✓
- October 1, 2030
-
Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Patent 10,946,101
Issued: March 16, 2021
Inventor(s): Tamarkin Dov & Gazal Elana & Papiashvili Irakliy & Hazot Yohan & Schuz David & Keynan Rita
Assignee(s): Vyne Therapeutics Inc.A substantially surface active agent free composition which includes a hydrophobic solvent, and/or a petrolatum, a paraffin wax and/or a fatty alcohol, a fatty acid and/or a wax and/or shea butter, with and without a propellant. A substantially surface active agent free composition, further comprising, a tetracycline antibiotic, or a vitamin D derivative, or one or more other active agents. A method of treatment using a substantially surface active agent free composition.
Patent expiration dates:
- October 1, 2030✓
- October 1, 2030
-
Patent 12,138,311
Patent expiration dates:
- October 1, 2030✓
- October 1, 2030
-
Topical tetracycline compositions
Patent 8,865,139
Issued: October 21, 2014
Inventor(s): Tamarkin Dov & Gazal Elana & Papiashvili Irakliy & Hazot Yohan & Schuz David & Keynan Rita
Assignee(s): Foamix Pharmaceuticals Ltd.A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.
Patent expiration dates:
- October 1, 2030✓✓
- October 1, 2030
-
Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Patent 8,945,516
Issued: February 3, 2015
Inventor(s): Tamarkin Dov & Gazal Elana & Papiashvili Irakliy & Hazot Yohan & Schuz David & Keynan Rita
Assignee(s): Foamix Pharmaceuticals Ltd.A substantially surface active agent free composition which includes a hydrophobic solvent, and/or a petrolatum, a paraffin wax and/or a fatty alcohol, a fatty acid and/or a wax and/or shea butter, with and without a propellant. A substantially surface active agent free composition, further comprising, a tetracycline antibiotic, or a vitamin D derivative, or one or more other active agents. A method of treatment using a substantially surface active agent free composition.
Patent expiration dates:
- October 1, 2030✓
- October 1, 2030
-
Topical tetracycline compositions
Patent 8,992,896
Issued: March 31, 2015
Inventor(s): Tamarkin Dov & Gazal Elana & Papiashvili Irakliy & Hazot Yohan & Schuz David & Keynan Rita
Assignee(s): Foamix Pharmaceuticals Ltd.A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.
Patent expiration dates:
- October 1, 2030✓✓
- October 1, 2030
-
Topical tetracycline compositions
Patent 9,675,700
Issued: June 13, 2017
Inventor(s): Tamarkin Dov & Gazal Elana & Papiashvili Irakliy & Hazot Yohan & Schuz David & Keynan Rita
Assignee(s): FOAMIX PHARMACEUTICALS LTD.A topical therapeutic hydrophobic breakable composition includes a carrier comprising, (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.
Patent expiration dates:
- October 1, 2030✓✓
- October 1, 2030
More about Zilxi (minocycline topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.